Elective discontinuation of Larotrectinib in pediatric patients with TRK fusion sarcomas and related mesenchymal tumors
Larotrectinib is a highly selective tropomyosin receptor kinase (TRK) inhibitor with efficacy in children with TRK fusion tumors. We evaluated patient outcomes after elective discontinuation of larotrectinib in the absence of disease progression in a protocol-defined wait-and-see subset analysis of...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2025
|
| In: |
Journal of clinical oncology
Year: 2025, Jahrgang: 43, Heft: 10, Pages: 1180-1187 |
| ISSN: | 1527-7755 |
| DOI: | 10.1200/JCO.24.00848 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1200/JCO.24.00848 Verlag, kostenfrei, Volltext: https://ascopubs.org/doi/10.1200/JCO.24.00848 
|
| Verfasserangaben: | Leo Mascarenhas, Steven G. DuBois, Catherine M. Albert, Stefan Bielack, Daniel Orbach, Noah Federman, Birgit Geoerger, Ramamoorthy Nagasubramanian, Yizhou Zhang, Julia Chisholm, Soledad Gallego Melcon, Hiroaki Goto, Daniel A. Morgenstern, Cormac Owens, Alberto S. Pappo, Sébastien Perreault, Johannes H. Schulte, Neerav Shukla, Christian Michel Zwaan, Natascha Neu, Vadim Bernard-Gauthier, Esther De La Cuesta, Cornelis M. van Tilburg, and Theodore W. Laetsch |
MARC
| LEADER | 00000naa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1942615175 | ||
| 003 | DE-627 | ||
| 005 | 20251126162803.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 251126s2025 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1200/JCO.24.00848 |2 doi | |
| 035 | |a (DE-627)1942615175 | ||
| 035 | |a (DE-599)KXP1942615175 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Mascarenhas, Leo |e VerfasserIn |0 (DE-588)1382741138 |0 (DE-627)1942616090 |4 aut | |
| 245 | 1 | 0 | |a Elective discontinuation of Larotrectinib in pediatric patients with TRK fusion sarcomas and related mesenchymal tumors |c Leo Mascarenhas, Steven G. DuBois, Catherine M. Albert, Stefan Bielack, Daniel Orbach, Noah Federman, Birgit Geoerger, Ramamoorthy Nagasubramanian, Yizhou Zhang, Julia Chisholm, Soledad Gallego Melcon, Hiroaki Goto, Daniel A. Morgenstern, Cormac Owens, Alberto S. Pappo, Sébastien Perreault, Johannes H. Schulte, Neerav Shukla, Christian Michel Zwaan, Natascha Neu, Vadim Bernard-Gauthier, Esther De La Cuesta, Cornelis M. van Tilburg, and Theodore W. Laetsch |
| 264 | 1 | |c 2025 | |
| 300 | |b Diagramme | ||
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online veröffentlicht: 27. Januar 2025 | ||
| 500 | |a Gesehen am 26.11.2025 | ||
| 520 | |a Larotrectinib is a highly selective tropomyosin receptor kinase (TRK) inhibitor with efficacy in children with TRK fusion tumors. We evaluated patient outcomes after elective discontinuation of larotrectinib in the absence of disease progression in a protocol-defined wait-and-see subset analysis of eligible patients where treatment resumption with larotrectinib was allowed if disease progressed. We also assessed the safety and efficacy of larotrectinib in all pediatric patients with sarcoma. This cohort included 91 patients (younger than 18 years) from two clinical trials: infantile fibrosarcoma (49), other soft tissue sarcomas or related mesenchymal tumors (41), and bone sarcoma (1). Treatment-related adverse events were of maximum grade 1 or 2 in 25% and 25% of patients, respectively. The overall response rate was 87% (95% CI, 78 to 93). In the wait-and-see analysis, 47 patients discontinued larotrectinib. Median time from discontinuation to disease progression was not reached. Sixteen patients had tumor progression during the wait-and-see period. All 16 patients resumed larotrectinib, and 15 (94%) achieved disease control, with 11 objective responses. Larotrectinib continues to demonstrate durable responses with favorable safety in children with TRK fusion sarcomas. Treatment discontinuation is feasible in select patients with objective response and clinical benefit noted in those who have disease progression after elective treatment discontinuation. | ||
| 700 | 1 | |a DuBois, Steven G. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Albert, Catherine M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bielack, Stefan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Orbach, Daniel |e VerfasserIn |4 aut | |
| 700 | 1 | |a Federman, Noah |e VerfasserIn |4 aut | |
| 700 | 1 | |a Geoerger, Birgit |e VerfasserIn |4 aut | |
| 700 | 1 | |a Nagasubramanian, Ramamoorthy |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zhang, Yizhou |e VerfasserIn |4 aut | |
| 700 | 1 | |a Chisholm, Julia |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gallego Melcon, Soledad |e VerfasserIn |4 aut | |
| 700 | 1 | |a Goto, Hiroaki |e VerfasserIn |4 aut | |
| 700 | 1 | |a Morgenstern, Daniel A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Owens, Cormac |e VerfasserIn |4 aut | |
| 700 | 1 | |a Pappo, Alberto S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Perreault, Sébastien |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schulte, Johannes H. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Shukla, Neerav |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zwaan, Christian Michel |e VerfasserIn |4 aut | |
| 700 | 1 | |a Neu, Natascha |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bernard-Gauthier, Vadim |e VerfasserIn |4 aut | |
| 700 | 1 | |a De La Cuesta, Esther |e VerfasserIn |4 aut | |
| 700 | 1 | |a Tilburg, Cornelis M. van |e VerfasserIn |0 (DE-588)1144664527 |0 (DE-627)1004962355 |0 (DE-576)495479519 |4 aut | |
| 700 | 1 | |a Laetsch, Theodore W. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical oncology |d Alexandria, Va. : American Society of Clinical Oncology, 1983 |g 43(2025), 10, Seite 1180-1187 |h Online-Ressource |w (DE-627)313116962 |w (DE-600)2005181-5 |w (DE-576)090887018 |x 1527-7755 |7 nnas |a Elective discontinuation of Larotrectinib in pediatric patients with TRK fusion sarcomas and related mesenchymal tumors |
| 773 | 1 | 8 | |g volume:43 |g year:2025 |g number:10 |g pages:1180-1187 |g extent:8 |a Elective discontinuation of Larotrectinib in pediatric patients with TRK fusion sarcomas and related mesenchymal tumors |
| 856 | 4 | 0 | |u https://doi.org/10.1200/JCO.24.00848 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://ascopubs.org/doi/10.1200/JCO.24.00848 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20251126 | ||
| 993 | |a Article | ||
| 994 | |a 2025 | ||
| 998 | |g 1144664527 |a Tilburg, Cornelis M. van |m 1144664527:Tilburg, Cornelis M. van |d 910000 |d 910500 |d 50000 |e 910000PT1144664527 |e 910500PT1144664527 |e 50000PT1144664527 |k 0/910000/ |k 1/910000/910500/ |k 0/50000/ |p 23 | ||
| 999 | |a KXP-PPN1942615175 |e 4814294700 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"physDesc":[{"noteIll":"Diagramme","extent":"8 S."}],"person":[{"given":"Leo","display":"Mascarenhas, Leo","role":"aut","family":"Mascarenhas","roleDisplay":"VerfasserIn"},{"role":"aut","display":"DuBois, Steven G.","given":"Steven G.","family":"DuBois","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","family":"Albert","display":"Albert, Catherine M.","role":"aut","given":"Catherine M."},{"given":"Stefan","role":"aut","display":"Bielack, Stefan","family":"Bielack","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","family":"Orbach","role":"aut","display":"Orbach, Daniel","given":"Daniel"},{"family":"Federman","roleDisplay":"VerfasserIn","given":"Noah","display":"Federman, Noah","role":"aut"},{"roleDisplay":"VerfasserIn","family":"Geoerger","given":"Birgit","display":"Geoerger, Birgit","role":"aut"},{"role":"aut","display":"Nagasubramanian, Ramamoorthy","given":"Ramamoorthy","family":"Nagasubramanian","roleDisplay":"VerfasserIn"},{"family":"Zhang","roleDisplay":"VerfasserIn","display":"Zhang, Yizhou","role":"aut","given":"Yizhou"},{"given":"Julia","display":"Chisholm, Julia","role":"aut","roleDisplay":"VerfasserIn","family":"Chisholm"},{"role":"aut","display":"Gallego Melcon, Soledad","given":"Soledad","roleDisplay":"VerfasserIn","family":"Gallego Melcon"},{"given":"Hiroaki","role":"aut","display":"Goto, Hiroaki","roleDisplay":"VerfasserIn","family":"Goto"},{"family":"Morgenstern","roleDisplay":"VerfasserIn","given":"Daniel A.","display":"Morgenstern, Daniel A.","role":"aut"},{"family":"Owens","roleDisplay":"VerfasserIn","display":"Owens, Cormac","role":"aut","given":"Cormac"},{"display":"Pappo, Alberto S.","role":"aut","given":"Alberto S.","roleDisplay":"VerfasserIn","family":"Pappo"},{"display":"Perreault, Sébastien","role":"aut","given":"Sébastien","family":"Perreault","roleDisplay":"VerfasserIn"},{"role":"aut","display":"Schulte, Johannes H.","given":"Johannes H.","family":"Schulte","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","family":"Shukla","display":"Shukla, Neerav","role":"aut","given":"Neerav"},{"given":"Christian Michel","role":"aut","display":"Zwaan, Christian Michel","family":"Zwaan","roleDisplay":"VerfasserIn"},{"given":"Natascha","role":"aut","display":"Neu, Natascha","family":"Neu","roleDisplay":"VerfasserIn"},{"given":"Vadim","display":"Bernard-Gauthier, Vadim","role":"aut","roleDisplay":"VerfasserIn","family":"Bernard-Gauthier"},{"roleDisplay":"VerfasserIn","family":"De La Cuesta","display":"De La Cuesta, Esther","role":"aut","given":"Esther"},{"roleDisplay":"VerfasserIn","family":"Tilburg","display":"Tilburg, Cornelis M. van","role":"aut","given":"Cornelis M. van"},{"role":"aut","display":"Laetsch, Theodore W.","given":"Theodore W.","family":"Laetsch","roleDisplay":"VerfasserIn"}],"note":["Online veröffentlicht: 27. Januar 2025","Gesehen am 26.11.2025"],"origin":[{"dateIssuedDisp":"2025","dateIssuedKey":"2025"}],"relHost":[{"origin":[{"publisher":"American Society of Clinical Oncology ; Lippincott Williams & Wilkins","dateIssuedKey":"1983","dateIssuedDisp":"1983-","publisherPlace":"Alexandria, Va. ; Baltimore, Md. [u.a.]"}],"id":{"issn":["1527-7755"],"eki":["313116962"],"zdb":["2005181-5"]},"titleAlt":[{"title":"official journal of the American Society of Clinical Oncology"},{"title":"JCO"},{"title":"Journal of clinical oncology legacy archive (ASCO)"}],"physDesc":[{"extent":"Online-Ressource"}],"note":["Fortsetzung der Druck-Ausgabe","Gesehen am 22.05.23"],"part":{"extent":"8","volume":"43","issue":"10","year":"2025","text":"43(2025), 10, Seite 1180-1187","pages":"1180-1187"},"pubHistory":["1.1983 -"],"corporate":[{"roleDisplay":"Herausgebendes Organ","role":"isb","display":"American Society of Clinical Oncology"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"language":["eng"],"recId":"313116962","disp":"Elective discontinuation of Larotrectinib in pediatric patients with TRK fusion sarcomas and related mesenchymal tumorsJournal of clinical oncology","title":[{"title":"Journal of clinical oncology","title_sort":"Journal of clinical oncology","subtitle":"JCO : an American Society of Clinical Oncology journal"}]}],"id":{"doi":["10.1200/JCO.24.00848"],"eki":["1942615175"]},"recId":"1942615175","title":[{"title_sort":"Elective discontinuation of Larotrectinib in pediatric patients with TRK fusion sarcomas and related mesenchymal tumors","title":"Elective discontinuation of Larotrectinib in pediatric patients with TRK fusion sarcomas and related mesenchymal tumors"}],"name":{"displayForm":["Leo Mascarenhas, Steven G. DuBois, Catherine M. Albert, Stefan Bielack, Daniel Orbach, Noah Federman, Birgit Geoerger, Ramamoorthy Nagasubramanian, Yizhou Zhang, Julia Chisholm, Soledad Gallego Melcon, Hiroaki Goto, Daniel A. Morgenstern, Cormac Owens, Alberto S. Pappo, Sébastien Perreault, Johannes H. Schulte, Neerav Shukla, Christian Michel Zwaan, Natascha Neu, Vadim Bernard-Gauthier, Esther De La Cuesta, Cornelis M. van Tilburg, and Theodore W. Laetsch"]},"language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"}} | ||
| SRT | |a MASCARENHAELECTIVEDI2025 | ||